US DoD awards $3 million to study Marinus epilepsy drug in FXS
This article was originally published in Scrip
Executive Summary
The US Department of Defense awarded $3 million to researchers at the University of California, Davis (UCD) to study Marinus Pharmaceuticals' lead drug candidate ganaxolone as a treatment for patients with Fragile-X Syndrome (FXS), the most common form of inherited intellectual disability, which results in learning and memory impairment, anxiety, hyperactivity and social avoidance.